PharmaPoint: Atopic Dermatitis – Global Drug Forecast and Market Analysis to 2022:Life Sciences Market Research Reports

Life Sciences Market Research Reports

Hate Your Job? Change your career in just 8 weeks with our UX Design immersive program in London. From our sponsors

PharmaPoint: Atopic Dermatitis – Global Drug Forecast and Market Analysis to 2022 Nov 12th 2013, 00:00, by vyankatesh Although the past decade has seen the atopic dermatitis market remain relatively unchanged and a saturated, highly genericized arena, the coming decade could see the launch of the first biologic, which will set a precedent and pave the way for others to follow suit. By the mid-to-late term of GlobalData's 2012 to 2022 forecast, Sanofi/Regeneron's dupilumab is expected to reshape the moderate and severe treatment landscape. Other events that are expected to invoke change to the previously stagnant atopic dermatitis market include the launch of a non-steroidal topical from Anacor, AN2728, generic erosion of branded topicals Protopic and Elidel in … Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=128987. Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/pharmapoint-atopic-dermatitis-global-drug-forecast-and-market-analysis-to-2022-market-report.html.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions